c‐erbB‐2 protein is expressed in hepatolithiasis and cholangiocarcinoma

Abstract

These results indicate that aberrant expression of c-erbB-2 protein is found in cholangiocarcinoma and also in noncancerous biliary proliferative lesions such as hepatolithiasis. These findings also suggest that c-erbB-2 oncogene participates not only in cholangiocarcinogenesis but also in biliary cell proliferation in non-neoplastic conditions.

JAK-STAT pathway in carcinogenesis: Is it relevant to cholangiocarcinoma progression?

“…In different tumors an autocrine loop between cytokines and ErbB receptors induces constitutive STAT3 activation [133,137] . In human non-neoplastic hepatic tissue ErbB2 mRNA and protein products have been found only in large mature bile ducts or have not been revealed at all [138][139][140] . Human gallstone disease and common bile duct ligation in rats are accompanied by appearance or elevation of ErbB2 expression in cholangiocytes as compared with normal liver but its expression was lower than in cases of cholangiocarcinoma [138,141,142] .…”

“…In human non-neoplastic hepatic tissue ErbB2 mRNA and protein products have been found only in large mature bile ducts or have not been revealed at all [138][139][140] . Human gallstone disease and common bile duct ligation in rats are accompanied by appearance or elevation of ErbB2 expression in cholangiocytes as compared with normal liver but its expression was lower than in cases of cholangiocarcinoma [138,141,142] . ErbB2 overexpression has been revealed in different human biliary tract cancer cell lines, xenobiotic induced rodent cholangiocarcinoma, as well as in human cholangiocarcinoma tissue samples.…”

Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma

“…These receptors share high sequence identity with each other and are coexpressed in various combinations in neoplasms. Thus far, of the four receptors, the expression of EGF-R and c-erbB-2 has been investigated in various neoplasms, including malignancies of the liver and biliary tract (Brunt and Swanson, 1992;Collier et al, 1992;Nakapoulou et al, 1994;Lee and Pirdas, 1995;Kira et al, 1997;Terada et al, 1998). The other two receptors, c-erbB-3 and c-erbB-4, have only been studied in depth for a few neoplasms (Sanidas et al, 1993;Simpson et al, 1995;Shintani et al, 1995;Haugen et al, 1996;Travis et al, 1996;Bobrow et al, 1997;Bodey et al, 1997;Chow et al, 1997;Ibrahim et al, 1997;Srinivasan et al, 1998Srinivasan et al, , 2000Suo et al, 1998;Freiss et al, 1999;Haussler et al, 1999;Kapitanovic et al, 2000;Kew et al, 2000), and little is known about their expression in hepatic malignancies.…”

EGFR and HER2 Expression in advanced Biliary Tract Cancer

“…In addition, there is increasing evidence that EHCC and IHCC respond differently to chemotherapy suggesting different biological properties of these two tumor subtypes of "cholangiocarcinoma" [25,26] . HER2 overexpression and amplification has been found in a range between 5% and 76% in BTC [14][15][16][17][18][19]24,27] . T his wide rang e may in par t ref lect the lack of standardized methodologies used within the different studies to assess HER2 status.…”

“…Overall, overexpression of EGFR and HER2 in tumor cells has been associated with a poor prognosis, but also offers the therapeutic option of pharmacologically targeting these receptors. To date, EGFR and HER2 overexpression has been reported in up to about 80% of BTC, mostly in small patient cohorts [14][15][16][17][18][19] . Nevertheless, there are no data regarding the correlation of immunohistochemical scores, determined by standardized methods, with clinical findings, including the overall survival of patients with advanced BTC treated by chemotherapy.…”